Sanofi to Acquire Principia Biopharma for $3.7 Billion
Sanofi announced on August 17, 2020, it has agreed to acquire Principia Biopharma for approximately $3.68 billion in cash, bolstering its research and development in autoimmune diseases.
Sanofi announced on August 17, 2020, that it will acquire Principia Biopharma Inc. for approximately $3.68 billion in cash. The deal aims to enhance Sanofi's research and development capabilities, particularly in the area of autoimmune diseases.
The acquisition grants Sanofi full control of Principia's Bruton's tyrosine kinase (BTK) inhibitor, SAR442168, which is being developed for multiple sclerosis and other central nervous system conditions. Sanofi anticipates that full ownership will streamline the drug's path to commercialization and allow for expanded development across various indications.
Principia's pipeline also includes rilzabrutinib, an oral BTK inhibitor with potential applications in several immunology and inflammation indications. A topical BTK inhibitor for immune-mediated dermatologic diseases, currently in Phase 1 trials, is also included in the transaction.
The move signifies Sanofi's strategy to accelerate its portfolio of next-generation treatments for autoimmune conditions. BTK inhibitors are designed to target signaling pathways in immune cells, potentially reducing inflammation and tissue damage associated with autoimmune disorders.